Legislative Action Center
Together we can help key policy makers at the federal and local levels better understand how their decisions on policy and legislation impact community oncology care. State and federal legislation can have a real impact on your bottom line, and ultimately how you deliver care, which is why it's so important that ACCC members bring their on-the-frontline perspectives to the legislative process.
2015 Cancer Policy Landscape
Transitioning Payments in Medicare
ACCC applauds the passage of H.R. 2, Medicare Access and CHIP Reauthorization Act (MACRA) in April 2015, bringing to an end the Sustainable Growth Rate and years of short-term patches to provider payment rates. MACRA also brings a transition to dual Medicare payment systems that emphasize value over volume: the Merit-Based Incentive Payment System (MIPS) and Alternative Payment Models (APM).
SGR is Over: What Will MACRA Mean for Providers?
On Wednesday, April 22, an ACCC members-only conference with Dan Todd, former Senior Health Counsel, Senate Finance Committee, provided a closer look at MACRA. An archived recording of the call will be available to ACCC members soon. Read a one-page call summary. View ACCC's MACRA Roadmap infographic here.
- Read ACCC’s press release on the passage of MACRA
- Read our ACCCBuzz blog, SGR is Over: What Does it Mean for Providers?
MACRA encourages providers to participate in Alternative Payment Models, such as the Oncology Care Model. Visit our Oncology Care Model Resource Center to see if this payment system suits your practice.
ACCC is dedicated to passing legislation at the state and Federal level which would require health insurance plans to cover orally administered chemotherapy at the same rate as IV-infused counterparts.
ACCC is working with a coalition to ensure oral parity legislation is reintroduced in the U.S. House and Senate. Federal legislation is needed in addition to state legislation, to ensure all insurance policies provide parity for oral treatments. ERISA plans and others fall outside of state regulation.
Oral chemotherapy may provide an easier, less intrusive way to fight various types of cancer, but unless Congress acts to create reimbursement equity between oral and IV-infused treatments, most patients will not be able to afford these oral treatment regimens.
ACCC has also worked with a coalition to pass state oral parity laws. 39 states have now passed such legislation. Please visit our coalition website for a detailed map of state laws.
Even though state laws are currently being passed, federal legislation is still required for two important reasons:
- Language of the laws varies across the states and only federal legislation will ensure the same protections for all patients; and
- State laws only impact state-regulated plans. Federal legislation is needed to cover self-insured plans (ERISA).
Prompt Pay Discount
Because Medicare reimburses using average sales price (ASP), the discount that is customarily provided to drug distributors by manufacturers when they pay promptly for drugs (Prompt Pay Discount) is not passed on to the providers who buy the drugs to give directly to their patients. Result: providers miss about 2 percent of the intended reimbursement on all drugs. Failure to exclude prompt pay discounts from the calculation of ASP threatens the current distribution model for specialty products and artificially lowers Part B reimbursement for physicians and other providers.